SARDA PROTEINS LTD. (SRDAPRT) Fair Value & Analysis
Consumer Defensive · IN · Market cap ₹161M
Strengths
Risks
Fair value as of: Aug 21, 2026
From 14 valuation models · updated today
Fair value updated Aug 21, 2026, revised from ₹74.38 to ₹74.57 (+0.3%) since Aug 13, 2026. Share price +10.2% over the past month.
A solid business, but screening 27% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹78.40). The favourable scenario is already priced in.
- Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band (₹69.79 to ₹78.40), unusually little disagreement for a valuation.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
60‑month range ₹0.0002 – ₹316.60 · fair‑value band ₹69.79 – ₹78.40 · the ₹102.66 price screens above the ₹74.57 fair value. Dashed = 300-day average. As of Aug 21, 2026.
Analysis
SARDA PROTEINS LTD. (SRDAPRT) currently trades at ₹102.66, while our model-based Fair Value estimate is ₹74.57, implying the stock looks roughly 27.4% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, SARDA PROTEINS LTD. generated revenue of ₹162M at a net margin of 4.0%. It earns a return on equity of 23.7%. Fundamentals as of Aug 21, 2026
Our scenario range runs from ₹69.79 (bear case) to ₹78.40 (bull case); at ₹102.66, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 71% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -14% fair-value upside, at -27%, SRDAPRT screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Asset-Based (₹748.13) versus Multiples (₹50.25). Highest evidence: Growth-Adj P/E (68).
Notify me when SRDAPRT reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 54
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sarda Proteins Ltd trades in edible oils and agri commodities in India. It is involved in trading mustard oil and mustard oil cake, as well as soya refined oil; and agricultural commodities, such as oil seeds, grains, and edible oils. The company also provides manpower services. Sarda Proteins Ltd was incorporated in 1991 and is based in Jaipur, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SARDA PROTEINS LTD. reported revenue of ₹242M in FY2025 versus ₹114M in FY2021, a compound +20.8%/yr. Reported net income was ₹51.0K in FY2025.
SRDAPRT screens 27% overvalued. Compare with Nestlé India Limited →
Peer Group
Packaged Foods · 658 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Packaged Foods median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Nestlé India Limited NESTLEIND | ₹1,507 | ₹362.37 | -76% |
| Britannia Industries Limited BRITANNIA | ₹5,511 | ₹1,765 | -68% |
| Tata Consumer Products Limited TATACONSUM | ₹1,062 | ₹327.27 | -69% |
| PT Indofood CBP Sukses Makmur Tbk ICBP | 7,550 IDR | 12,864 IDR | +70% |
| Samyang Foods Co 003230 | 1,219,000 KRW | 1,010,543 KRW | -17% |
| Vietnam Dairy Products Joint Stock Company VNM | 61,600 VND | 52,858 VND | -14% |
| Patanjali Foods Limited PATANJALI | ₹350.95 | ₹144.77 | -59% |
| PT Mayora Indah Tbk, MYOR | 1,650 IDR | 2,699 IDR | +64% |
| PT Cisarua Mountain Dairy Tbk CMRY | 4,610 IDR | 4,350 IDR | -6% |
| Nongshim Co 004370 | 389,500 KRW | 530,619 KRW | +36% |
Compare SARDA PROTEINS LTD. with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is SARDA PROTEINS LTD. (SRDAPRT) overvalued or undervalued?
What is the fair value of SRDAPRT?
What is the quality score of SRDAPRT?
What is the revenue of SARDA PROTEINS LTD. (SRDAPRT)?
What is the net profit margin of SRDAPRT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SARDA PROTEINS LTD. and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.